

nie s primární profylaxí G-CSF, kožní toxicita (typická akneformní vyrážka 3. stupně a tato byla příčinou od 18. cyklu léčby k redukci cetuximabu. Jinak ale infusion-related reak-

ce nenastaly, neobjevila se nauzea, průjem, anémie. Tato salvage terapie prodloužila za velmi dobré kvality života pacienta léčebnou periodu o více než rok! A bezesporu byla

důvodem i toho nejdůležitějšího, co pacienta zajímá – a to délky jeho života. A zde k tomuto uvedená rechallenge anti-EGFR léčba bezesporu přispěla!

LITERATURA

1. Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. *Lancet Oncol.* 2016;17(10):1426-1434.
2. Schwartzberg LS, Rivera F, de Valdecilla M, et al. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. *J Clin Oncol.* 2014;32(21):2240-2255.
3. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Lond Engl.* 2013;381:303-312.
4. Mayer RJ, Van Cutsem E, Falcon A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med.* 2015;372:1909-1919.
5. Cremolini C, Rossini D, Dall'Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. *JAMA Oncol.* 2018;343-350.
6. Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? *Ann Oncol Off Eur Soc Med Oncol.* 2012;23:2313-2318.
7. Tsuji A, Nakamura M, Watanabe T, et al. P-243 Phase II of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. *Ann Oncol.* 2018:29.
8. Osawa H, Shinozaki E, Nakamura M, et al. P-481 Phase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial. *Ann Oncol.* 2018:29.
9. Siena S, George P, Gerald P, et al. Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect of outcomes. *Ann Oncol.* 2017:28.
10. Tanioka H, Asanlo M, Yoshida R, et al. Cetuximab re-treatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. *Oncol Lett.* 2018;16:3674-3680.
11. Stein A, Binder M, Goekkurt E, et al. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCR): Final results of the phase II AVETUX trial (AIO-KRK-0216). *Gastrointestinal Cancer Symposium 2020. J Clin Oncol.* 2020;36:15 Suppl.
12. Martinelli E, Ciardiello D, Martini G, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: Challenges and future perspectives. *Ann Oncol.* 2020;31:30-40.
13. Troiani T, Martinelli E, Ciardiello D, et al. Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon. *Gastrointestinal Cancer Symposium 2019. J Clin Oncol.* 2019; 37:4 Suppl.
14. Pietrantonio F, Perrone F, Biondani P, et al. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. *Cancer Biol Ther.* 2013;14:1098-1103.
15. Wasan H, Meade AM, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. *Lancet Oncol.* 2014;15:631-639.
16. Kaechle V, von Wichert G, Adler G, et al. Response to re-introduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with cetuximab-containing regimen. *Oncology.* 2008;74:1236-6.
17. Metges J, Raoul J, Achour N, et al. PANERB study: Panitumumab after cetuximab-based regimen failure. *J Clin Oncol.* 2010;28:e14000.
18. Marino A, Calio C, Sponziello F, et al. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience. *Tumori.* 2015;101:524-528.
19. Kiss I, Mlcochova J, Bortliceck Z, et al. Efficacy and toxicity of panitumumab after progression on cetuximab and predictive value of MiR-31-5p in metastatic wild-type KRAS colorectal cancer patients. *Anticancer Res.* 2016;36:4955-4959.
20. Forst AA, McMahon JA, Wilding G, et al. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. *Oncology.* 2013;84:210-213.
21. Feng Q, Wei Y, Ren L, et al. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. *Oncotarget.* 2016;7:1380-1396.
22. Ciardiello D, Normanno N, Martinelli E, et al. Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab. *Ann Oncol.* 2015;26:iv120-121.
23. Vladimirova LY, Abramova NA, Kit OI. Treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC): continuation of anti-EGFR therapy while switching chemotherapy regimen. *ASCO 2016; Abstract 744.*
24. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.3506.
25. Available from: www.clinicaltrials.gov/ct2/show/NCT03227926.
26. Available from: www.clinicaltrials.gov/ct2/show/NCT02934529.
27. Available from: www.clinicaltrials.gov/ct2/show/NCT03311750.
28. Available from: www.clinicaltrials.gov/ct2/show/NCT03524820.
29. Available from: www.clinicaltrials.gov/ct2/show/NCT03087071.
30. Available from: www.clinicaltrials.gov/ct2/show/NCT02316496.
31. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143.



SUPPLEMENTUM

Imunoterapie

vstoupila do 1. linie léčby zhoubných nádorů jícnu, gastroezofageální janky a žaludku

MUDr. Ondřej Kubeček, Ph.D., MUDr. Peter Grell, Ph.D.